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AlbuminBlood-contacting medical devices have been associated with severe clinical complications, such as
thrombus formation, triggered by the activation of the coagulation cascade due to the adsorption of cer-
tain plasma proteins on the surface of biomaterials. Hence, the coating of such surfaces with antithrom-
botic agents has been used to increase biomaterial haemocompatibility. Biomaterial-induced clotting
may also be decreased by albumin adsorption from blood plasma in a selective and reversible way, since
this protein is not involved in the coagulation cascade. In this context, this paper reports that the immo-
bilization of the thrombin inhibitor D-Phe-Pro-D-Arg-D-Thr-CONH2 (fPrt) onto nanostructured surfaces
induces selective and reversible adsorption of albumin, delaying the clotting time when compared to
peptide-free surfaces. fPrt, synthesized with two glycine residues attached to the N-terminus (GGfPrt),
was covalently immobilized onto self-assembled monolayers (SAMs) having different ratios of carboxyl-
ate-hexa(ethylene glycol)- and tri(ethylene glycol)-terminated thiols (EG6-COOH/EG3) that were specif-
ically designed to control GGfPrt orientation, exposure and density at the molecular level. In solution,
GGfPrt was able to inactivate the enzymatic activity of thrombin and to delay plasma clotting time in
a concentration-dependent way. After surface immobilization, and independently of its concentration,
GGfPrt lost its selectivity to thrombin and its capacity to inhibit thrombin enzymatic activity against
the chromogenic substrate n-p-tosyl-Gly-Pro-Arg-p-nitroanilide. Nevertheless, surfaces with low concen-
trations of GGfPrt could delay the capacity of adsorbed thrombin to cleave ﬁbrinogen. In contrast, GGfPrt
immobilized in high concentrations was found to induce the procoagulant activity of the adsorbed
thrombin. However, all surfaces containing GGfPrt have a plasma clotting time similar to the negative
control (empty polystyrene wells), showing resistance to coagulation, which is explained by its capacity
to adsorb albumin in a selective and reversible way. This work opens new perspectives to the improve-
ment of the haemocompatibility of blood-contacting medical devices.
 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.1. Introduction
Failure of some blood-contacting medical devices has been
associated with thrombus formation initiated by the adsorption
of certain blood proteins onto the biomaterial surface. This pro-
tein layer can induce complex and interlinked processes, such
as activation of the intrinsic coagulation system and adhesion
and activation of platelets [1]. Thrombin is a key proteolyticenzyme of the coagulation cascade since it catalyses the conver-
sion of soluble ﬁbrinogen into ﬁbrin, a major and essential com-
ponent of the blood clot. This protease also activates FXIII, which
cross-links and stabilizes the ﬁbrin mesh, induces platelet activa-
tion and stimulates its own generation supporting blood clotting
[2]. Heparin, an indirect thrombin inhibitor, has been widely used
as a systemic anticoagulant and as a coating of medical devices to
delay biomaterial-induced thrombosis [3,4]. However, heparin
only inhibits thrombin after its binding to endogenous
antithrombin (AT), which may be reduced in patients having AT
deﬁciency or sepsis [5]. Moreover, nonspeciﬁc heparin binding
to plasma proteins (i.e. ﬁbrinogen) and to proteins secreted by
platelets (i.e. platelet factor 4 (PF4)) not only decreases its
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thrombocytopenia induced by heparin–PF4 complexes. In addi-
tion, the heparin–AT complex does not inhibit ﬁbrin-bound
thrombin [6,7].
Alternatively, direct thrombin inhibitors directly block the
active site of both soluble and ﬁbrin-bound thrombin and do not
require the presence of an endogenous cofactor [6]. Hirudin, a
highly potent and speciﬁc natural thrombin inhibitor [8], has also
been explored as a biomaterials coating but its low biological activ-
ity and stability after surface immobilization limits its utilization
for short-term applications [9–13].
Small peptides have several advantages over biomolecules (i.e.
proteins) to be used as a biomaterials coating: (1) easier and less
expensive production; (2) greater stability (longer shelf-life); (3)
generally, lower immunogenicity [14]; (4) more controllable cou-
pling to the surface [15]. Small synthetic direct thrombin inhibitor
peptides containing the amino acid sequence D-Phe–Pro–Arg,
which resembles the speciﬁc thrombin binding of human ﬁbrino-
peptide A [16], have also been explored [17–19]. The small peptide,
D-Phe–Pro–Arg–Pro–Gly (fPRPG) [20], which was previously
immobilized by us onto ethylene glycol (EG)-terminated self-
assembled monolayers (SAMs), inhibited the activity of adsorbed
thrombin in a concentration-dependent way but lost most of its
thrombin-binding selectivity in the presence of plasma proteins
[18]. The direct and irreversible thrombin inhibitor, D-Phe-Pro-
ArgCH2Cl (PPACK), was also recently immobilized onto poly(pro-
pylene-alt-maleic anhydride) (PPMA) thin ﬁlms using EG as a
spacer [19]. Nevertheless, most of the PPACK molecules lost their
thrombin inhibitory capacity after immobilization, prompting us
to develop a new immobilization strategy, which is presented
thereafter.
Several small synthetic peptides with the general formula
D-Phe(P3)-Pro(P2)-D-Arg(P1)-P10-CONH2, with different D- and
L-amino acids at P10 position, were evaluated for their ability to
interact with the thrombin active site and block its proteolytic
activity [21–24]. The D-Phe and Pro residues in positions P3 and
P2 interact with thrombin S3 and S2 pockets, respectively
[23,25]. The D-conﬁguration of Arg at the P1 position was used to
avoid the proteolytic cleavage of the Arg–P10 bond. D-Phe-Pro-D-
Arg-D-Thr-CONH2 (fPrt) displayed the highest thrombin inhibitory
activity [23]. Moreover, this peptide was able to completely inhibit
thrombin-induced platelet aggregation [22,26].
This work aims at determining if fPrt can be used as a coating to
avoid biomaterials-induced blood coagulation. fPrt was extended
at its N-terminal end by two glycines (GGfPrt) to provide a small
spacer and to improve its exposure after surface immobilization.
GGfPrt was evaluated regarding thrombin enzymatic inactivation
and plasma coagulation before and after immobilization onto
nanostructured surfaces, prepared by mixing long-chain carboxyl-
ate-hexa(ethylene glycol)-terminated thiol (EG6-COOH) with
short-chain tri(ethylene glycol)-terminated thiol (EG3). EG3 was
used to resist non-speciﬁc protein adsorption [27] and the long-
chain EG6-COOH to provide COOH terminal groups to facilitate
peptide coupling by its N-terminus with a better surface exposure
(Scheme 1). Different concentrations of immobilized GGfPrt were
obtained using SAMs prepared with different ratios of EG6-
COOH/EG3.
Surfaces were characterized using ellipsometry, infrared
reﬂection absorption spectroscopy (IRRAS) and X-ray photoelec-
tron spectroscopy (XPS). Protein adsorption was followed using
125I-labelled proteins. The effect of GGfPrt on thrombin proteo-
lytic activity was evaluated by assessing the protease ability to
cleave the chromogenic substrate n-p-tosyl-Gly-Pro-Arg-p-nitro-
anilide and ﬁbrinogen in solution. The anticlotting capacity of
the developed surfaces was evaluated using the recalciﬁed plas-
ma clotting assay.2. Materials and methods
2.1. GGfPrt synthesis
2.1.1. Materials and instrumentation
General solvents and reagents were all of analytical quality
and acquired from Sigma–Aldrich (Madrid, Spain). Fmoc-pro-
tected amino acids, Fmoc-Rink Amide-MBHA LL resin
(0.36 mmol g1) and coupling reagent O-(benzotriazol-1-yl)-
N,N,N0,N0-tetramethyluronium-hexaﬂurophosphate (HBTU) were
provided by Novabiochem (VWR International, Portugal). Peptide
synthesis was performed on a Liberty1 Microwave Peptide Syn-
thesizer (CEM Corporation, Mathews, NC, USA). Peptide analysis
by high-performance liquid chromatography (HPLC) was done
on a Hitachi-Merck LaChrom Elite system equipped with a qua-
ternary pump, a thermostatted (Peltier effect) automated sampler
and a diode-array detector (DAD). An LCQ-DecaXP LC-MS system
from ThermoFinnigan, equipped with both a DAD detector and an
electrospray ionization-ion trap mass spectrometer (ESI/IT MS),
was used also for peptide analysis. Peptide amino acid composi-
tion determination was performed by amino acid analysis (AAA)
on a Biochrom 30 (CCiT, University of Barcelona).
2.1.2. Peptide synthesis
The hexapeptide (C-terminal amide) was assembled by Fmoc/
tBu solid-phase peptide synthesis methodologies assisted with
microwave (MW) energy [28,29]. The resin was pre-conditioned
for 15 min in N,N-dimethylformamide (DMF) and then transferred
into the MW-reaction vessel. The initial Fmoc deprotection step
was carried out using 20% piperidine in DMF containing 0.1 M of
1-hydroxybenzotriazole (HOBt) in two MW irradiation pulses:
30 s at 24 W plus 3 min at 28 W, in both cases the temperature
did not exceed 75 C. The C-terminal amino acid was then coupled
to the deprotected Rink Amide resin, using 5 M equivalents (eq) of
the Fmoc-protected amino acid in DMF (0.2 M), 5 eq of 0.5 M
HBTU/HOBt in DMF and 10 eq of 2 M N-ethyl-N,N-diisopropyl-
amine (DIPEA) in N-methylpyrrolidone (NMP); the coupling step
was carried out for 5 min at 20 WMW irradiation, with maximum
temperature reaching 75 C. The remaining amino acids were
sequentially coupled in the C?N direction by means of similar
deprotection and coupling cycles, except for incorporation of
Fmoc-D-Arg(Pbf)-OH, whose coupling was done in two steps:
25 min with no MW irradiation (room temperature, RT) followed
by 5 min coupling at 25 W.
Following completion of sequence assembly, the peptide was
released from the resin, with concomitant removal of side-chain
protecting groups, by a 3 h-acidolysis at RT using a triﬂuoroacetic
acid (TFA)-based cocktail [28] containing water and triisopropysi-
lane (TIS) as scavengers (TFA/H2O/TIS 95:2.5:2.5 v/v/v). Crude
product was puriﬁed by reverse-phase liquid chromatography to
give the target peptide, as conﬁrmed by HPLC, LC-ESI/IT MS and
AAA.
2.2. Surface preparation
2.2.1. Gold substrates
2.2.1.1. Gold plate. Gold substrates (1  1 cm2) for surface charac-
terization were prepared as described elsewhere [30]. Brieﬂy, chro-
mium (5 nm) and gold (25 nm) ﬁlms were deposited by ion beam
sputtering onto silicon wafers. The thin layer of chromium was
used to improve adhesion of gold to silicon.
2.2.1.2. Gold wires. For protein adsorption and clotting assays,
99.99% purity gold wires (Goodfellow Cambridge Ltd) 0.20 mm in
diameter and 30 cm total length were used. These wires were
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Scheme 1. Schematic representation of GGfPrt immobilization onto mixed EG6/EG3-SAMs.
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with the optical path of the microplate spectrophotometer light
beam, enabling the real time follow-up of thrombin activity and
clotting time. An additional reason for using gold wires was avoid-
ing the interference of the silicon surface on the opposite side of
gold planar substrates during immersion assays. Previous electro-
chemical studies performed by us [31] demonstrated that SAMs
prepared in gold wires are as well organized and reproducible as
those on planar substrate.2.2.2. Preparation of mixed SAMs (EG6-COOH/EG3)
Pure solutions of (1-Mercapto-11-undecyl)tri(ethylene glycol)
(EG3; SH-(CH2)11(OCH2CH2)3–OH; 99%, SensoPath Technologies,
Inc.) and (1-Mercapto-11-undecyl)hexa(ethylene glycol) carbox-
ylic acid (EG6-COOH; SH-(CH2)11(OCH2CH2)6-OCH2COOH; 99%,
SensoPath Technologies, Inc.) were prepared at a concentration of
2 mM in absolute ethanol. Mixtures of the EG3 and EG6-COOH-ter-
minated thiols were obtained by mixing the pure solutions in
different ratios at ﬁnal concentrations of 1 mM. All solutions were
prepared under dry nitrogen atmosphere inside a glove box.
Immediately before being used, gold substrates (plates and
wires) were cleaned with a freshly prepared ‘‘piranha’’ solution
(7 parts concentrated H2SO4 (95% (v/v), BDH Prolabo) and 3 parts
H2O2 (30% (v/v), Merck)) for 5 and 30 min, respectively (Caution:
this solution reacts violently with many organic materials and
should be handled with great care). Then, gold substrates were
rinsed sequentially with absolute ethanol (99.9% (v/v), Merck),
Milli-Q water and absolute ethanol for 3 min in an ultrasound bath
and dried with a stream of argon.
Gold substrates were immersed in the alkanethiol solutions and
incubated at RT for 24 h under nitrogen environment. Obtained
SAMs were washed twice in absolute ethanol for 2 min in an ultra-
sound bath, dried with a stream of nitrogen and maintained in an
argon environment inside a sealed petri dish until use.2.2.3. GGfPrt immobilization on mixed SAMs
GGfPrt was immobilized on mixed SAMs in two sequential reac-
tion steps as described in Scheme 1.2.2.3.1. Activation of the COOH groups of mixed SAMs. Mixed SAMs
were immersed in a freshly prepared Milli-Q water solution of
NHS (N-hydroxysuccinimide, Sigma) and EDC (1-(3-dimethylami-
nopropyl)-N0-ethylcarbodiimide hydrochloride, Sigma) at a ﬁnal
concentration of 0.05 and 0.20 M, respectively. After 1 h at RTand static conditions, NHS-activated SAMs were washed three
times with Milli-Q water and dried with a stream of argon.
2.2.3.2. Immobilization of peptide (GGfPrt) onto NHS-activated SAMs.
NHS-activated SAMs were immersed in a 1 mM GGfPrt solution
prepared in sodium phosphate buffer (25 mM, pH 8.0) for 24 h at
RT and 100 rpm. As control, the same reaction was performed
without the peptide (only phosphate buffer). All the solutions were
kept under nitrogen atmosphere. After immobilization, SAMs were
washed three times with Milli-Q water for 5 min at 150 rpm and
RT, dried with a stream of pure argon and preserved in an argon
environment until use.
2.3. Surfaces characterization
2.3.1. Ellipsometry
Monolayers thickness was determined using an EP3 Imaging
Ellipsometer (Nanoﬁlm Surface Analysis). This ellipsometer was
operated in a polarizer-compensator-sample-analyser (PCSA)
mode (null ellipsometry). The light source was a solid-state laser
with a wavelength of 532 nm. The gold substrate refractive index
(n) and extinction coefﬁcient (k) were determined using a delta
and psi spectrum with a variation angle between 66 and 76.
These measurements were made in four zones to correct for any
instrument misalignment. To determine the thickness of the SAMs,
the same kind of spectrum was used and n and k for the organic
layer were set as 1.45 and zero, respectively.
2.3.2. Infrared reﬂection absorption spectroscopy (IRRAS)
IRRAS measurements were performed on a FTIR spectropho-
tometer (model 2000, Perkin Elmer) coupled with VeeMax II Acces-
sory (PIKE) and a liquid-nitrogen-cooled MCT detector. The
instrument was continuously purged with dry nitrogen for 3 min
before data collection and during measurements to eliminate
water vapor absorption. For each SAM, a gold surface was used
as the background. The incident light was p-polarized and spectra
were collected using the 80 grazing angle reﬂection mode. For
each sample and reference, 100 scans were collected with 4 cm1
resolution. Before IRRAS measurements, all SAMs were placed in
a vacuum chamber overnight to avoid water absorption.
2.3.3. X-ray photoelectron spectroscopy (XPS)
XPS measurements were carried out at CEMUP (Centro de Mate-
riais da Universidade do Porto) on a VG Scientiﬁc ESCALAB 200A
(UK) spectrometer using magnesium Ka (1253.6 eV) as radiation
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Survey spectra were collected over a range of 0–1150 eV with an
analyser pass energy of 50 eV. High-resolution C(1s), O(1s), N(1s),
S(2p) and Au(4f) spectra were collected with an analyser pass en-
ergy of 20 eV. The effect of the electric charge was corrected by the
reference of the carbon peak (285 eV). The binding energy (BE)
scales were referenced by setting the Au4f7/2 BE to 84.0 eV. All
the spectra were ﬁtted using an XPS peak ﬁtting program
(XPSPEAK Version 4.1). All the carbon spectra were ﬁtted using
asymmetrical 70% Gaussian/30% Lorentzian proﬁles.2.4. Protein adsorption studies
2.4.1. Protein radiolabelling
Quantiﬁcation of adsorbed protein on the different monolayers
was performed using 125I-labelled proteins. Human a-thrombin
(Haematologic Technologies Inc., 1 mg ml1 in 50 mM sodium
phosphate, 150 mM sodium chloride, pH 6.5; 3961 U mg1) and
human serum albumin (HSA; Sigma–Aldrich, Ref. A3782) were la-
belled using the iodogen method [32] as previously described [18].
The yield of the iodination reaction was 97% for thrombin and 96%
for HSA as determined by the precipitation of the 125I-labelled
proteins with 20% trichloroacetic acid (TCA, Merck). 125I-labelled
proteins were added to unlabelled protein solutions (thrombin,
HSA, human plasma or serum) in PBSI (0.01 M phosphate buffered
saline (PBS) with 0.01 M of NaI) in order to achieve a ﬁnal thrombin
activity of 1.5  109 cpmmg1 and a ﬁnal HSA activity of 5  107 -
cpmmg1. These activities are higher than those previously used
by us [18,33] and the percentage of labelled to unlabelled protein
used (20%) was similar to that described by others [17]. Moreover,
these labelled solutions were prepared using the minimum cpm by
mg of unlabelled protein necessary to detect at least 100 cpm per
sample. PBSI was used to suppress the binding of free 125I ion
(present in trace amounts relative to nonradioactive iodide) as
previously described [34–37].2.4.2. Protein adsorption on surfaces
Each gold and SAMs wire was placed in a single well of 96-well
plates (polystyrene non-treated microplate, non-binding, Greiner
Bio-One), previously ﬁlled with 100 ll PBSI to completely cover
the sample. PBSI was used to avoid the adsorption of free 125-io-
dine to gold that could interfere with results. After 30 min of equil-
ibration with PBSI, 100 ll protein solutions (twofold concentrated
in PBSI) were added to each well, resulting in a ﬁnal 20 lg ml1 hu-
man thrombin solution (corresponding to approximately half of
prothrombin concentration in human plasma (978 nM) [38,39])
or 400 lg ml1 HSA solution (1% of albumin concentration in
human plasma [39]). Protein adsorption was carried out at 37 C
for 30 min. After adsorption, samples were rinsed three times with
PBS and gamma activities were counted inside radioimmunoassay
tubes. Surface protein concentration was calculated using the
following equation:
Proteinðlg=m2Þ ¼ CountsðcpmÞ  Csolutionðlg=mlÞ
Asolutionðcpm=mlÞ  SAðm2Þ ð1Þ
where Counts are the radioactivity measurements from the surface,
Csolution and Asolution are the concentration and the speciﬁc activity of
the protein solution, respectively, and SA is the wire surface area.2.4.3. Competitive adsorption studies
To evaluate the selectivity of GGfPrt-SAMs towards thrombin or
HSA in the presence of serum or plasma proteins, the following
competitive studies were conducted:(a) Adsorption of 125I-thrombin (20 lg ml1) in PBS and 125I-
thrombin (20 lg ml1) in 1% human serum. Human serum
(PAA Laboratories) was prepared from citrated plasma con-
taining all clotting factors except ﬁbrinogen.
(b) Adsorption of 125I-HSA (400 lg ml1) in PBS and 125I-HSA
(400 lg ml1) in 1% citrated human plasma (containing
400 lg ml1 albumin [39]). Citrated human plasma was
prepared from blood obtained from the Portuguese Blood
Institute (IPS) according to their guidelines and as previously
reported [40].
2.4.4. Exchangeability studies
Exchangeability tests were carried out by immersing the sur-
faces with pre-adsorbed 125I-thrombin (30 min pre-adsorption as
described in Section 2.4.2) in human serum or with pre-adsorbed
125I-HSA in citrated human plasma, at 37 C for 24 h. Samples were
then rinsed three times with PBS and residual radioactivity was
counted.
2.5. Thrombin activity studies
2.5.1. Effect of soluble GGfPrt on thrombin activity
The ability of the GGfPrt hexapeptide to inhibit thrombin
hydrolytic activity in solution was determined by UV–Vis
spectrophotometry (Biotek PowerWave HT microplate spectropho-
tometer, model: RPRWI340/96) using the chromogenic substrate
n-p-tosyl-Gly-Pro-Arg-p-nitroanilide (Sigma) [41]. Thrombin
solution (5.34 nM) and peptide solutions (5.34 lM–2 mM) were
pre-incubated for 15 min at 37 C in 96-well plates. After incuba-
tion, the chromogenic substrate was added at a ﬁnal concentration
of 160 lM. The reaction was followed by measuring the variation
of the absorbance at 405 nm every 15 s for at least 5 min. All
solutions were prepared in PBS.
2.5.2. Activity of the surface adsorbed thrombin
The activity of surface adsorbed thrombin was determined by
measuring its capacity to cleave the chromogenic substrate n-p-to-
syl-Gly-Pro-Arg-p-nitroanilide and to cleave ﬁbrinogen to ﬁbrin.
Surfaces with pre-adsorbed thrombin (prepared as described in
Section 2.4.2) were placed in 96-well plates and incubated at
37 C with: (1) the chromogenic substrate (5.34 mM in PBS) or
(2) ﬁbrinogen (4 mg ml1 in PBS, corresponding to the upper con-
centration of the normal range of ﬁbrinogen in human plasma
[39]). The absorbance of solutions was followed at 405 nm every
30 s for at least 2 h.
The activity of adsorbed thrombin to cleave the chromogenic
substrate was quantiﬁed in terms of reaction rate (abs min1).
Fibrinogen clotting by adsorbed thrombin was detected by a
sharp increase in absorbance. Fibrinogen clotting time was identi-
ﬁed as the time when the measured value of absorbance was 0.002
units larger than the average of the measurements from the previ-
ous 2 min.
2.6. Recalciﬁed plasma clotting time assay
The recalciﬁed plasma clotting time was determined using the
spectrophotometric detection method previously described [40].
Brieﬂy, calcium (CaCl2) to a ﬁnal concentration of 20 mM was
added to the citrated human plasma, pre-warmed at 37 C, quickly
mixed in a vortex and rapidly added to 96-well plates with GGfPrt
or the different surfaces. Absorbance at 405 nm was measured
every 30 s for 60 min in the spectrophotometer at 37 C. A sharp
increase in absorbance indicates the start of clot formation. Clot-
ting time was deﬁned as the time span from the beginning of the
assay until the moment the measured value of absorbance was
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measurements.2.7. Statistical analysis
The experimental results are presented as the mean ± the
standard deviation (SD). The statistical signiﬁcance of differences
between mean values was determined using the ANOVA one-way
test and comparison between groups was performed using the
Tukey method. Values of p < 0.05 were considered statistically
signiﬁcant.3. Results
3.1. GGfPrt effect on thrombin activity and clotting time
In solution, GGfPrt was able to inhibit the proteolytic activity of
thrombin in a concentration-dependent manner (Fig. 1a). Throm-
bin activity was almost completely inhibited after pre-incubation
with 1 or 2 mM of GGfPrt (GGfPrt/thrombin of 2  105 and
4  105, respectively). Further, a dose-dependent increase of plas-
ma clotting time by GGfPrt in solution could be observed
(Fig. 1b), with values higher than 1 h for a GGfPrt concentration
of 2 mM.(a) 100
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Fig. 1. GGfPrt effect in solution on (a) thrombin proteolytic activity and (b) plasma
clotting time. (a) Thrombin was pre-incubated with the indicated concentrations of
inhibitor for 15 min. Inhibition levels were determined by measuring the activity of
thrombin against a chromogenic substrate after 5 min reaction. All results are
statistically signiﬁcantly different. (b) Recalciﬁed plasma was incubated with
GGfPrt and absorbance at 405 nm was measured every 30 s for 60 min. Clotting
time was determined as the time at which a sharp increase in absorbance (0.02
units larger than the average of the two previous measurements) was detected. All
results are statistically signiﬁcantly different.3.2. Characterization of mixed SAMs
SAMs prepared from pure EG6-COOH and EG3-terminated
thiols and their mixtures were characterized using ellipsometry
and IRRAS.
An increase in monolayer thickness with increase of the
percentage of EG6-COOH-thiol in solution is shown in Fig. 2a.
SAMs thickness had a slight enhancement from 2 to 2.5 nm when
the percentage of EG6-COOH in solution raised from 0 to 60,
followed by a considerable thickness increase until 4 nm, as the
percentage of this thiol was increased from 60 to 100.
The relationship between the incorporation of the EG6-COOH-
thiol on the monolayer and its percentage in solution is repre-
sented in Fig. 2b. The percentage of COOH on the monolayer was
calculated based on SAMs thickness using the following equation
[42]:
EG6 COOHSurfaceð%Þ ¼ TmixedSAM TpureEG3DTpureðEG6 COOH EG3Þ  100 ð2Þ
where EG6-COOHsurface (%) is the percentage of the EG6-COOH in a
mixed SAM with a thickness TmixedSAM, DTpure(EG6-COOH-EG3) is
the difference between the thickness of EG6-COOH and EG3-termi-
nated pure SAMs (4 and 2 nm, respectively). The chemisorption of
the EG3-thiol was favourable when compared to EG6-COOH-thiol,
since for an equimolar solution of both thiols, there was a predom-
inance of EG3 on the monolayer (72–86%).
IRRAS was performed to analyse the degree of crystallinity and
molecular orientation of ethylene glycol (EG) groups on SAMs
(Fig. 3). A strong absorption band at 1130 cm1 assigned to the
C–O–C stretching mode along with a broad shoulder at4.0
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1232 S.C. Freitas et al. / Acta Biomaterialia 10 (2014) 1227–12371145 cm1 was observed in all SAMs prepared with EG3 (pure
and mixed SAMs), which is a characteristic of amorphous EG moi-
eties [27]. In the case of 100% EG6-COOH-SAMs, the absorption
band allocated to the C–O–C stretching mode was shifted to
1117 cm1, which, in combination with absorption bands at 1244
and 1347 cm1 assigned to CH2 twist and wagging modes, respec-
tively, can be attributed to an oriented crystalline helical phase
[27,43]. Nevertheless, the broad shoulder at 1145 cm1 on this
SAM suggested an amorphous phase. Thus, domains of oriented
helical crystalline phase coexist with an amorphous phase in
100% EG6-COOH-SAMs, as described elsewhere [43]. The orienta-
tion of the alkyl chains relative to the surface can be deduced from
the relative intensities of their CH2-stretching vibrations, detected
in infrared region from 2800 to 3000 cm1. A crystalline helical
conformation with high packing density has a characteristic strong
CH stretching peak at 2892 cm1. All pure and mixed SAMs pre-
sented a broad band from 2840 to 2960 cm1 (data not shown),
suggesting an amorphous and less oriented conformation of EG
groups on gold. This type of conformation of EG onto SAMs was de-
scribed to be responsible for its non-fouling characteristics, namely
for its protein adsorption resistance [27].
Although SAMs prepared from a solution with 5% and 10% of
EG6-COOH did not show thickness differences with regard to pure
EG3-SAMs, the incorporation of EG6-COOH below 10% was referred
to in the literature as ideal for the biological activity of immobi-
lized ligands [42,44–46]. Therefore, SAMs prepared from solutions
containing 5%, 20% and 80% of EG6-COOH were used for posterior
GGfPrt immobilization and subsequent assays.0.07 0.04
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Fig. 5. Ratio between nitrogen and gold (N/Au) of mixed SAMs after NHS activation
(NHS-SAMs) and after immersion in buffer with or without GGfPrt (GGfPrt-SAMs
and buffer-SAMs, respectively).3.3. GGfPrt immobilization on mixed SAMs
The immobilization of the peptide GGfPrt on SAMs was
followed using IRRAS and XPS. For simplicity, mixed SAMs are
referred through the text with a nomenclature that represents
the percentage of the EG6-COOH used in solution.
IRRAS spectra of each GGfPrt immobilization step onto SAMs
prepared with 80% EG6-COOH-thiol are illustrated in Fig. 4. After
treatment with EDC and NHS, an absorption band centred at
1746 cm1, characteristic of the C@O stretch of the NHS estergroups, was observed [47,48]. After incubation with peptide, the
characteristic absorption bands of the peptide bonds (amide I at
1690 ± 45 cm1 and amide II at 1540 ± 60 cm1) [49] were
detected. Simultaneously, the 1746 cm1 NHS band disappeared,
suggesting total reaction with the peptide. Additionally, activated
NHS-SAMs incubated in buffer (without peptide) did not present
the peak assigned to NHS, suggesting ester hydrolysis back to free
COOH groups. Adsorption of GGfPrt to non-activated SAMs was not
detected by IRRAS (data not shown), indicating that all the immo-
bilized peptide was covalently bound to the activated SAMs.
Similar results were obtained for peptide immobilization onto
20% EG6-COOH-SAMs. However, peptide immobilization onto 5%
EG6-COOH-SAMs was not detected using this technique (data not
shown).
Surface atomic composition of the different SAMs was deter-
mined by XPS. The ratio between nitrogen and gold (N/Au) of SAMs
prepared with 5%, 20% and 80% of EG6-COOH in solution, after NHS
activation and after incubation in buffer with and without GGfPrt,
S.C. Freitas et al. / Acta Biomaterialia 10 (2014) 1227–1237 1233is shown in Fig. 5. The presence of nitrogen on NHS-SAMs demon-
strated the conversion of surface carboxyls into the respective NHS
esters. After immersion in buffer, the amount of nitrogen decreased
to a residual value, indicating that the pre-formed NHS esters were
hydrolysed back to their carboxyl precursors. When incubated
with GGfPrt, N/Au increased with regard to buffer-SAMs and
NHS-SAMs, demonstrating the success of peptide immobilization.
The amount of immobilized GGfPrt was 7 and 6 times higher
on 80% EG6-COOH SAMs than on 5% and 20% EG6-COOH SAMs,
respectively. The absence of nitrogen on mixed SAMs without the
EDC/NHS activation step and immersed in GGfPrt (data not shown)
indicates the absence of adsorbed GGfPrt.
3.4. Protein adsorption studies
Thrombin adsorption was much lower in all SAMs when
compared to gold (Fig. 6a). However, thrombin adsorption to SAMs
increased with GGfPrt immobilized in low amounts (GGfPrt-5 and
GGfPrt-20-SAMs). A high concentration of immobilized GGfPrt
(GGfPrt-80-SAMs) was not related to an increase of thrombin
adsorption.
When adsorption was performed in the presence of serum pro-
teins, thrombin adsorption was even lower in all SAMs and gold,
demonstrating their lack of selectivity for thrombin.61
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Fig. 6. (a) 125I-thrombin adsorption on gold and SAMs with or without immobilized
GGfPrt from a pure thrombin solution and from 1% human serum solution
(20 lg ml1 thrombin). Percentages indicate the decrease of adsorbed thrombin
due to the presence of serum proteins. The difference in the amount of thrombin
adsorbed from buffer is statistically signiﬁcant between Au and other surfaces,
GGfPrt-SAMs and related buffer-SAMs and GGfPrt-5-SAMs and GGfPrt-20-SAMs.
Thrombin adsorbed from serum is statistically signiﬁcantly different between Au
and other surfaces and between different GGfPrt-SAMs. (b) Retention of 125I-
thrombin previously adsorbed on gold and SAMs with or without immobilized
GGfPrt, after 24 h incubation in human serum. ⁄Statistically signiﬁcant difference
compared to all other conditions.The exchangeability of adsorbed thrombin with serum proteins
is presented in Fig. 6b. Thrombin retention was very low in all
SAMs, mainly in the presence of immobilized GGfPrt, where
thrombin retention decreased as the peptide concentration
increased.
Regarding albumin adsorption, immobilized GGfPrt increased
albumin adsorption to SAMs in a concentration-dependent manner
(Fig. 7a). Albumin adsorption onto surfaces with peptide did not
decrease in the presence of plasma proteins as was observed for
the control surfaces (Au and 80-EG6-COOH without peptide), a
strong indication that albumin binds to GGfPrt-surfaces in a spe-
ciﬁc way. Moreover, albumin also adsorbs onto surfaces presenting
a high number of –COOH groups (without peptide), as previously
described by us [31]. However, the presence of competitive plasma
proteins decreased albumin adsorption to 80-EG6-COOH, demon-
strating that, on these surfaces, adsorption was non-speciﬁc. Even
more, albumin adsorption on GGfPrt-SAMs increased when incu-
bated with plasma, indicating an elevated selectivity of immobi-
lized GGfPrt to albumin. The increase in HSA adsorption from
protein mixtures or plasma when compared to pure solution was
also observed on other albumin–surface systems [30,33,50,51].
This was explained by the increase in total protein concentration
that may lead to preferential adsorption of HSA [33,50]. The
exchangeability of already adsorbed albumin by other proteins42
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Fig. 9. (a) Fibrinogen clotting time induced by thrombin pre-adsorbed on different
surfaces. All conditions are statistically signiﬁcantly different between them. (b)
1234 S.C. Freitas et al. / Acta Biomaterialia 10 (2014) 1227–1237present in the plasma medium (namely albumin) was higher on
GGfPrt-SAMs than on the other surfaces (Fig. 7b).
3.5. Activity of surface adsorbed thrombin
The activity of adsorbed thrombin against a chromogenic sub-
strate was very low in all the surfaces except on SAMs with higher
amounts of GGfPrt (GGfPrt-80-SAMs) (Fig. 8a and b). Thrombin
activity was higher when was adsorbed on GGfPrt-SAMs, especially
in high peptide concentration (GGfPrt-80-SAMs). The activity of
adsorbed thrombin on all GGfPrt-SAMs was >100 times higher
than in solution. In opposition, when adsorbed on gold, thrombin
loses 74% of its activity compared to the free protease.
Activity of adsorbed thrombin was also evaluated by measuring
the ﬁbrinogen clotting time. Fig. 9a shows that thrombin adsorbed
on gold and GGfPrt-80-SAMs was able to cleave ﬁbrinogen in a
very short time (7 and 3 min, respectively). In opposition, throm-
bin adsorbed onto GGfPrt-20-SAMs had the longest ﬁbrinogen
clotting time (43 min) suggesting that the adsorbed thrombin
might be in an arrangement that avoids cleavage of ﬁbrinogen.
Moreover, ﬁbrinogen clotting time normalized to the amount of
adsorbed thrombin (Fig. 9b) demonstrated that the rate of this
protease to cleave ﬁbrinogen is similar when adsorbed onto
GGfPrt-5-SAMs and GGfPrt-20-SAMs.
3.6. Recalciﬁed plasma clotting time assay
Plasma recalciﬁed clotting time assay evaluates the tendency of
a biomaterial to induce coagulation by the adsorption of contact
activation proteins (intrinsic pathway). From a biomaterials per-
spective, this assay is performed without any kind of procoagulant
agents (FXII activator and phospholipids), which are required in0.05 ± 0.02 
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Fig. 8. (a) Hydrolytic activity of adsorbed thrombin towards a chromogenic
substrate. ⁄Statistically signiﬁcant difference compared to all other conditions. (b)
Thrombin activity normalized to the quantity of adsorbed thrombin (ratio between
rate of reaction (absorbance min1) and adsorbed thrombin (mg m2)). ⁄Statisti-
cally signiﬁcant difference compared to all other conditions.
Thrombin hydrolytic activity towards ﬁbrinogen normalized to the quantity of
adsorbed thrombin (ratio between ﬁbrinogen clotting time (min) and adsorbed
thrombin (ng cm2)). ⁄Statistically signiﬁcant difference compared with all other
conditions.other coagulation assays (i.e. activated partial thromboplastin time
assay), since these compounds could mask the effect of the bioma-
terial [40,52,53].
Since this assay was performed with surfaces inserted in non-
treated polystyrene (PS) 96-well plates, the clotting time is bound
to be affected by the PS surface. Then, PS wells without substrates
were used as the negative control (20 ± 0.5 min) (Fig. 10). GGfPrt-
SAMs have clotting times similar to PS, showing that GGfPrt avoids
the activation of the coagulation system induced by GGfPrt-free
surfaces (gold and buffer-80-SAMs). The clotting time of plasma
on PS wells was different in the experiments with peptide in20.0 ± 0.5
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Fig. 10. Clotting time of recalciﬁed plasma in non-treated polystyrene 96-well plate
(PS) in the presence of gold and SAMs. ⁄Statistically signiﬁcant difference compared
to all other conditions.
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observed differences between assays were due to the previously
reported variability of different plasma lots [54,55].
4. Discussion
D-Phe-Pro-D-Arg-D-Thr-CONH2 (fPrt), recently described as a
potent direct thrombin inhibitor [22,24], with an inhibition con-
stant (Ki) of 0.92 lM [23], was evaluated for its capacity to be used
as a coating to avoid biomaterials-induced coagulation. This pep-
tide was covalently bound to nanostructured surfaces speciﬁcally
designed to control its orientation, exposure and density at a
molecular level. To ensure correct peptide orientation, i.e. main-
taining available the amino acids that directly interact with the
active site of thrombin, fPrt must be coupled by its N-terminus.
For that, SAMs with different percentages of COOH groups were
prepared using mixtures of two alkanethiols, EG6-COOH- and
EG3-thiols, as described by Lahiri et al. [42]. Following activation
with NHS/EDC in aqueous buffer at pH 8, the reactive NHS ester
groups selectively react with the N-terminus of the peptide: GGfPrt
immobilization through the peptide’s arginine side chain or
through both this side chain and the N-terminal amine is rather
unlikely, since the arginine side chain (pKa 12) is still protonated
at pH 8, thus not being a strong enough nucleophile to compete
with the terminal amine (pKa 7.6–8) for nucleophilic addition to
the surface’s reactive NHS ester groups.
To increase peptide exposure from the surface, these mixed
SAMs were prepared using COOH-thiols with a longer chain length
than EG3-thiol. In addition, fPrt was synthesized with two glycine
residues attached to the N-terminus to act as a small spacer
(GGfPrt). The percentage of EG6-COOH incorporation was used to
control GGfPrt surface density and the EG groups to avoid non-spe-
ciﬁc protein adsorption [56]. The incorporation of COOH groups on
SAMs was conﬁrmed using ellipsometry, which demonstrated that
EG3 chemisorbs preferentially on gold surfaces compared to EG6-
COOH, contrary to what has been previously described [42]. An
explanation could reside in the different containers used in SAMs
preparation, since it is known that different alkanethiols could ad-
sorb differently to the container used. During this work, polypro-
pylene ﬂasks were used instead of glass scintillation vials
employed by Lahiri et al. [42]. Our results were reproducible for
all assays (three replicates of each condition in seven assays).
The amorphous and less oriented conformation of the EG groups,
necessary to avoid non-speciﬁc protein adsorption [27], was dem-
onstrated using IRRAS.
GGfPrt was immobilized onto SAMs prepared from solutions
with 5%, 20% and 80% of EG6-COOH. The amount of immobilized
GGfPrt was about seven and six times higher on GGfPrt-80-SAMs
than on GGfPrt-5 and GGfPrt-20-SAMs, respectively.
The success of GGfPrt immobilization was demonstrated by IR-
RAS and XPS. Both techniques were able to detect the conversion
of COOH groups in NHS ester and the subsequent GGfPrt coupling
by the appearance of the characteristic absorption bands of NHS
and peptide (IRRAS) and the increase of the nitrogen amount
(XPS).
GGfPrt adsorption was not detected after incubation of non-
activated SAMs in GGfPrt solution, suggesting that all the peptide
that was found on activated SAMs was covalently coupled. The
presence of NHS groups after the incubation of activated SAMs in
buffer was residual, demonstrating the absence of free activated
groups that could induce non-speciﬁc protein adsorption.
Thrombin adsorption on SAMs was very low when compared to
bare gold surface, but always well above the detection limit of the
technique used (0.05 ng cm2) [34,57]. Thrombin adsorption on
SAMs corresponds to less than 5% of the theoretical maximum
for a thrombin monolayer, which was estimated to be between271 and 301 ng cm2 for molecules lying perpendicular or parallel
to the surface [58]. This lower thrombin adsorption can be related
to the non-fouling nature of the EG3 background, which can
counteract the uptake of the protein of interest as described in
other protein–surface systems [40,59–61]. Immobilization of
GGfPrt in higher concentrations did not increase thrombin adsorp-
tion since although GGfPrt-80-SAMs have six times more peptide
than GGfPrt-20-SAMs, the amount of adsorbed thrombin was sim-
ilar (13 ± 0.8 and 12 ± 1.1 ng cm2, respectively). This can be re-
lated to the higher density of immobilized peptides, leading to
(a) peptide aggregation with consequent loss of their availability
to bind thrombin and/or (b) steric hindrance by peptide-bound
thrombin, making free adjacent peptides unavailable for binding
to more thrombin molecules [44].
It was also demonstrated that immobilized GGfPrt loses its
selectivity to bind thrombin, since when adsorption was per-
formed in the presence of serum proteins, the amount of adsorbed
thrombin decreased by 70%.
In solution, GGfPrt was able to inhibit thrombin proteolytic
activity and delay plasma coagulation in a concentration-depen-
dent way. However, its thrombin inhibitory capacity was 10 times
lower than that of the peptide without the two glycines (data not
shown). After immobilization, GGfPrt improved the hydrolytic
activity of adsorbed thrombin towards the small chromogenic
substrate, n-p-tosyl-Gly-Pro-Arg-p-nitroanilide, when compared
to the soluble form (>100 times). Although adsorbed in the same
concentration, thrombin adsorbed on GGfPrt-80-SAMs was
approximately four times more active at cleaving the chromogenic
substrate than when adsorbed on GGfPrt-20-SAMs. This could be
related with the high peptide density that could lead to a second-
ary binding (i.e. non-active site directed), thereby exposing cata-
lytically active thrombin molecules. Moreover, thrombin
adsorbed onto GGfPrt-80-SAMs had the lowest ﬁbrinogen clotting
time in opposition to thrombin adsorbed on GGfPrt-20-SAMs and
GGfPrt-5-SAMs that presented the highest ﬁbrinogen clotting
time. These results revealed that the enzymatic proﬁle of adsorbed
thrombin is dependent on GGfPrt concentration, highlighting the
importance of the ligand surface density for the optimal ligand–
biomolecule binding as described for other applications
[18,42,62–64].
In contrast to SAMs with GGfPrt, bare gold surface adsorbs ele-
vated concentrations of thrombin, in a non-selective and non-
reversible way. Thrombin adsorbed on gold has low enzymatic
activity to the chromogenic substrate, which has been associated
with its adsorption in a random orientation and with an alteration
of its conformation after adsorption on gold that can hinder its cat-
alytic centre and not to the speciﬁc blocking of its active site
[18,40]. However, thrombin adsorbed on gold can cleave ﬁbrinogen
into ﬁbrin in a very short time, indicating that some thrombin
molecules are adsorbed in an orientation that favours the interac-
tion with ﬁbrinogen. Regarding buffer-80-SAMs (without GGfPrt),
adsorbed thrombin has a low enzymatic activity against the chro-
mogenic substrate, which can also be attributed to its non-speciﬁc
adsorption on the COOH groups of buffer-80-SAM in an orientation
that hinders its catalytic centre. However, ﬁbrinogen clotting time
of this surface (buffer-80-SAM) was lower than GGfPrt-5 and
GGfPrt-20-SAMs but much higher than gold and GGfPrt-80-SAMs.
It is likely that thrombin’s natural substrate, ﬁbrinogen, can out-
compete the COOH groups of buffer-80-SAM for thrombin binding,
as ﬁbrinogen must bind to thrombin’s positively charged exosite I
for proper processing. Buffer-80-SAMs presented higher ﬁbrinogen
clotting time than gold, indicating that these surfaces had fewer
molecules of thrombin able to cleave ﬁbrinogen, in good agree-
ment with the amount of total thrombin adsorbed onto Buffer-
80-SAMs being much lower than in the gold surface (9 times less;
Fig. 6).
1236 S.C. Freitas et al. / Acta Biomaterialia 10 (2014) 1227–1237Nevertheless, immobilized GGfPrt avoided the decrease of
plasma clotting time observed with GGfPrt-free surfaces (Au and
buffer-80-SAMs) and with other biomedical reference materials
such as medical grade poly(ether urethane), poly(ethylene tere-
phthalate) or poly(dimethyl siloxane) [33]. Since it was observed
that GGfPrt-SAMs did not bind thrombin in a selective way, the de-
lay on plasma clotting time can be explained by the adsorption of
other proteins such as albumin, which are not involved in the acti-
vation of the coagulation system. Immobilized GGfPrt induces albu-
min adsorption on SAMs in a selective and reversible way. The
selectivity of GGfPrt to albumin can be explained by the albumin
ability to bind threonine [65], the terminal amino acid of GGfPrt.
Surfaces that adsorb albumin in a selective and reversibleway avoid
the adsorption of blood contact proteins (FXII, high molecular
weight kininogen (HMWK) and prekallikrein (PK)) that trigger the
intrinsic coagulation and also the adsorption of adhesive proteins
such as ﬁbrinogen that mediate platelet adhesion and aggregation
[33,63,66]. Furthermore, surfaces coated with albumin have been
found to reduce platelet and leukocyte adhesion and aggregation
to synthetic materials, preventing subsequent thrombus formation
in vitro [67]. However, pre-coating a biomaterial with albumin has
several disadvantages, namely: (1) denaturation on the surface,
being recognized as an altered protein; (2) desorption, exposing
the bare surface to activate coagulation and related processes; (3)
conformational changes, exposing groups that induce coagulation;
(4) exchange by other proteins that are involved in coagulation
[68]. The development of surfaces that can attract and bind albumin
from the bloodstream in a selective and reversible way has been the
focus of several researchers as a way to increase the haemocompat-
ibility of biomaterials [66,69,70]. Albumin adsorption studies
showed that GGfPrt surfaces adsorb albumin in a selective and
reversible way, suggesting increased haemocompatibility.
The decrease of plasma clotting time induced by the gold sur-
face when compared to the control (PS) was related with the
adsorption/activation of blood contact proteins, such as HMWK
[55,61] and FXII [55]. COOH groups can bind the contact proteins
HMWK, FXII and PK [71], which explain the faster plasma clotting
time of buffer-80-SAMs with regard to the control (PS).
This work demonstrated that after surface immobilization,
GGfPrt lost its capacity to bind and inactivate the procoagulant
activity of thrombin, but opens new perspectives for its utilization
as a biomaterial coating due to its high selectivity to albumin, since
surfaces that adsorb albumin in a selective and reversible way are
described to avoid biomaterials-induced thrombus formation.5. Conclusion
GGfPrt, a small thrombin inhibitor peptide, was successfully
synthesized and immobilized in different concentrations on
COOH-EG6/EG3 mixed SAMs. It was demonstrated that, after
immobilization, GGfPrt avoids the coagulation activation induced
by GGfPrt-free SAMs, due to the adsorption of albumin, a protein
that is not involved in the activation of the coagulation system,
in a selective and reversible way. This work opens new outlooks
to improve the haemocompatibility of biomaterials.Disclaimer
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